{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:23:45Z","timestamp":1768706625140,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.mehy.2019.109377","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T01:55:44Z","timestamp":1566352544000},"page":"109377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease"],"prefix":"10.1016","volume":"132","author":[{"given":"Rafael Vincent M.","family":"Manalo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109377_b0005","article-title":"Atypical parkinsonism revealing a late onset, rigid and akinetic form of Huntington\u2019s disease","volume":"696953","author":"Ciammola","year":"2011","journal-title":"Case Rep Neurol Med"},{"key":"10.1016\/j.mehy.2019.109377_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.mehy.2019.109377_b0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.68.2.238","article-title":"Late onset levodopa responsive Huntington\u2019s disease with minimal chorea masquerading as Parkinson plus syndrome","volume":"68","author":"Reuter","year":"2000","journal-title":"J Neurol Neurosurg Pysch"},{"key":"10.1016\/j.mehy.2019.109377_b0020","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/mds.870130610","article-title":"Neurophysiological abnormalities in the Westphal variant of Huntington\u2019s disease","volume":"13","author":"T\u00f6pper","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.mehy.2019.109377_b0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0165-0173(00)00039-4","article-title":"Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington\u2019s disease","volume":"34","author":"Cicchetti","year":"2000","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.mehy.2019.109377_b0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","article-title":"Huntington\u2019s disease genetics","volume":"1","author":"Myers","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.mehy.2019.109377_b0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/hmg\/ddi477","article-title":"Deletion of the triple repeat encoding polyglutamine within the mouse Huntington\u2019s gene results in subtle behavior\/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro","volume":"15","author":"Clabough","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.mehy.2019.109377_b0045","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nn1702","article-title":"Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function","volume":"9","author":"Yanai","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0050","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington\u2019s disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr Trends Neurol"},{"key":"10.1016\/j.mehy.2019.109377_b0055","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/iub.111","article-title":"Protein misfolding inside cells: the case of huntingtin and Huntington\u2019s disease","volume":"60","author":"Hatters","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.mehy.2019.109377_b0060","first-page":"9832839","article-title":"Pathophysiology of motor dysfunction in Parkinson\u2019s disease as the rationale for drug treatment and rehabilitation","volume":"2016","author":"Magrinelli","year":"2016","journal-title":"Parkinson Dis"},{"key":"10.1016\/j.mehy.2019.109377_b0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson\u2019s disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2019.109377_b0070","first-page":"39","article-title":"Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective","volume":"2","author":"Brocks","year":"1999","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.mehy.2019.109377_b0075","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.mehy.2019.109377_b0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0976-3147.143197","article-title":"Psychiatric aspects of Parkinson\u2019s disease","volume":"6","author":"Grover","year":"2015","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.mehy.2019.109377_b0085","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(73)90398-X","article-title":"Reduced glutamic acid decarboxylase activity of post-mortem brain in Huntington\u2019s chorea","volume":"1","author":"Bird","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2019.109377_b0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JHD-160200","article-title":"Targeting the cholinergic system to develop a novel therapy for Huntington\u2019s disease","volume":"5","author":"D\u2019Souza","year":"2016","journal-title":"J Huntington Dis"},{"key":"10.1016\/j.mehy.2019.109377_b0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","article-title":"Treatment of Huntington disease","volume":"15","author":"Videnovic","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.mehy.2019.109377_b0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fnins.2018.00137","article-title":"Caffeine protects dopaminergic neurons from dopamine-induced neurodegeneration via synergistic adenosine-dopamine D2-like receptor interactions in transgenic Caenorhabditis elegans","volume":"12","author":"Manalo","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fncel.2017.00027","article-title":"Current concepts on the pathophysiological relevance of dopaminergic receptors","volume":"11","author":"Ledonne","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41419-017-0221-2","article-title":"Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson\u2019s disease","volume":"9","author":"Tozzi","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.mehy.2019.109377_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","article-title":"Tyrosine hydroxylase and regulation of dopamine synthesis","volume":"508","author":"Daubner","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.mehy.2019.109377_b0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/28190","article-title":"Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins","volume":"394","author":"Miesenb\u00f6ck","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2019.109377_b0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pharmtox.46.120604.141146","article-title":"Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances","volume":"48","author":"Chaudhry","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.mehy.2019.109377_b0135","doi-asserted-by":"crossref","first-page":"11869","DOI":"10.1073\/pnas.97.22.11869","article-title":"Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles","volume":"97","author":"Sulzer","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.mehy.2019.109377_b0140","first-page":"181","article-title":"Intraneuronal dopamine-quinone synthesis: a review","volume":"2000","author":"Sulzer","year":"2000","journal-title":"Neurotox Res"},{"key":"10.1016\/j.mehy.2019.109377_b0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.mehy.2019.109377_b0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00702-006-0450-5","article-title":"Functional effects of neuromelanin and synthetic melanin in model systems","volume":"113","author":"Double","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.mehy.2019.109377_b0155","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.67.7_suppl_2.S8","article-title":"A proposed dual role of neuromelanin in the pathogenesis of Parkinson\u2019s disease","volume":"67","author":"Zecca","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2019.109377_b0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fnagi.2016.00196","article-title":"Neuromelanin imaging and dopaminergic loss in Parkinson\u2019s disease","volume":"8","author":"Isaias","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.mehy.2019.109377_b0165","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3892\/mmr.2017.6823","article-title":"Dopamine attenuates ethanol-induced neuroapoptosis in the developing rat retina via the cAMP\/PKA pathway","volume":"16","author":"Han","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.mehy.2019.109377_b0170","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0042-6989(97)00296-4","article-title":"Amino acid neurotransmitters in the retina: a functional overview","volume":"38","author":"Wu","year":"1998","journal-title":"Vision Res"},{"key":"10.1016\/j.mehy.2019.109377_b0175","first-page":"5629","article-title":"Determination of neurotransmitter levels in rodent retina","volume":"52","author":"Farmen","year":"2011","journal-title":"Invest Ophthal Visual Sci"},{"key":"10.1016\/j.mehy.2019.109377_b0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2478\/10004-1254-60-2009-1927","article-title":"Comparison of ethanol and acetaldehyde toxicity in rat astrocytes in primary culture","volume":"60","author":"Sarc","year":"2009","journal-title":"Arh Hig Rada Toksikol"},{"key":"10.1016\/j.mehy.2019.109377_b0185","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1073858417712667","article-title":"Ethanol and the developing brain: inhibition of neuronal activity and neuroapoptosis","volume":"24","author":"Lotfullina","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.mehy.2019.109377_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0074-7742(10)91008-8","article-title":"Ethanol action on dopaminergic neurons in the ventral tegmental area: interaction with intrinsic ion channels and neurotransmitter inputs","volume":"91","author":"Morikawa","year":"2010","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.mehy.2019.109377_b0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-8993(90)90811-O","article-title":"The GABA and substance P input to dopaminergic neurons in the substantia nigra of the rat","volume":"529","author":"Bolam","year":"1990","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2019.109377_b0200","first-page":"115","article-title":"The neurochemistry of Huntington\u2019s chorea","volume":"4","author":"Spokes","year":"1981","journal-title":"TINS"},{"key":"10.1016\/j.mehy.2019.109377_b0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1471-4159.2002.00804.x","article-title":"The role of dopamine in motor symptoms in the R6\/2 transgenic mouse model of Huntington\u2019s disease","volume":"81","author":"Hickey","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2019.109377_b0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1471-4159.2006.03762.x","article-title":"Dopamine release is severely compromised in the R6\/2 mouse model of Huntington\u2019s disease","volume":"97","author":"Johnson","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2019.109377_b0215","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/NEN.0b013e3181ee005d","article-title":"Hyperdopaminergic status in experimental Huntington disease","volume":"69","author":"Jahanshashi","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.mehy.2019.109377_b0220","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1331.2008.02390.x","article-title":"Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington\u2019s disease","volume":"16","author":"van Oostrom","year":"2009","journal-title":"Eur J neurol"},{"key":"10.1016\/j.mehy.2019.109377_b0225","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0006-8993(77)90538-8","article-title":"Striatal lesions with kainic acid: neurochemical characteristics","volume":"127","author":"Schwarcz","year":"1977","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2019.109377_b0230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0306-4522(81)90168-8","article-title":"Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain","volume":"6","author":"Fonnum","year":"1981","journal-title":"Neuroscience"},{"key":"10.1016\/j.mehy.2019.109377_b0235","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.7901908","article-title":"Oxidative stress, glutamate, and neurodegenerative disorders","volume":"262","author":"Coyle","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.mehy.2019.109377_b0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmhg.2017.07.004","article-title":"The endoplasmic reticulum stress response in disease pathogenesis and pathophysiology","volume":"19","author":"Manalo","year":"2018","journal-title":"Egypt J Med Hum Genet"},{"key":"10.1016\/j.mehy.2019.109377_b0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","article-title":"Dopamine and glutamate in Huntington\u2019s disease: a balancing act","volume":"16","author":"Andr\u00e9","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.mehy.2019.109377_b0250","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pbb.2006.11.003","article-title":"Neurogenesis decreases during brain maturation from adolescence to adulthood","volume":"86","author":"He","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.mehy.2019.109377_b0255","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.cell.2014.01.044","article-title":"Neurogenesis in the striatum of the adult human brain","volume":"156","author":"Ernst","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2019.109377_b0260","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1073\/pnas.1114137109","article-title":"Striatum processes reward differently in adolescents versus adults","volume":"109","author":"Sturman","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mehy.2019.109377_b0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tins.2017.09.004","article-title":"Making dopamine connections in adolescence","volume":"40","author":"Hoops","year":"2017","journal-title":"Trends Neurosci"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719307091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719307091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:17:48Z","timestamp":1759691868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719307091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":53,"alternative-id":["S0306987719307091"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109377","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109377"}}